Strong increase in drug expenditure in March

Fri, 2020 / 05 / 15
The Federal Union of German Associations of Pharmacists (ABDA) announced a sharp increase in drug expenditure for March 2020, as reported by the Federal Association of the Pharmaceutical Industry (BPI).

The Federal Union of German Associations of Pharmacists (ABDA) announced a sharp increase in drug expenditure for March 2020, as reported by the Federal Association of the Pharmaceutical Industry (BPI). Even without taking vaccines into account, expenditures rose by 25 % to 3.84 billion euros compared to the same month last year (March 2019). This is due to a 13.7 % increase in the number of prescriptions and an 11.8 % increase in packages sold. There is also a noticeable trend towards larger package sizes, which contribute to the increased expenditure. The figures represent the SHI payments to pharmacies, including VAT, after deduction of discounts from manufacturers and pharmacies and patient co-payments. Discount agreements were not considered. For the first quarter of 2020, pharmaceutical expenditure totalled 10.38 billion euros, almost 12 % more than in the same quarter of the previous year.

Vaccination expenditure also rose dramatically in March, reaching a total of 153 million euros for the first quarter of 2020, around 43 % more than in the first quarter of 2019.

Although no official data were available for April at the time of reporting, pharmacies reported about declining drug sales for the month of April. This sharp rise in costs in March and the presumed decline in April suggest, in addition to increased acute care, a habit of doctors of chronically ill patients in March seeking to reduce the frequency of doctor visits during the corona pandemic, to protect their vulnerable patients.

Expenditure on drugs and vaccines represents a considerable cost factor for the statutory health insurance funds in Germany. The AMNOG procedure, introduced in 2011, enables a benefit-assessment-based negotiation of costs for patented novel drugs. With the strategic support of SKC Beratungsgesellschaft, numerous highly innovative drugs have already mastered AMNOG market access. As experts, we support our clients primarily in the areas of benefit dossier and evaluation, market understanding, strategic pricing and stakeholder management.

Sources (in German):

 

About the author

Ihre Ansprechpartnerin Dipl.-Biologin Dr. rer. nat. Angelika Deichmann
Dipl.-Biologin Dr. rer. nat. Angelika Deichmann
Fon: +49 511 64 68 14 0 – 0
Fax: +49 511 64 68 14 18
to the top
Important information about the corona virus

Dear business associates,
despite the pandemic crisis, SKC is up and running. Due to significant investments in digital and agile technology and processes in the recent years, we are offering our comprehensive professional services in an unrestricted way.

The office in Hannover is manned and accessible through all established channels.

Stay healthy!
The SKC-Team